Navigation Links
Genyous Biomed Announces Private Placement Financing
Date:1/29/2009

Company will leverage multivalent drug development platform, expand oncology pipeline, and explore potential for other chronic diseases

REDWOOD SHORES, Calif., Jan. 29 /PRNewswire/ -- Genyous Biomed International Inc. ("Genyous") announced today that it has entered into a $36 million private placement agreement with multiple closings. Under the terms of this financing, investments will be made in three tranches: $12 million before March 31, 2009, $12 million before December 31, 2009 and $12 million before December 31, 2010. Genyous anticipates that these funds will cover operations for three years. "This financing will enable us to further develop our oncology pipeline," said James Dao, Chairman & CEO of Genyous. "In addition, we will be able to leverage our MFMT(TM) drug development platform and extend into other chronic diseases of interest which include BPH, COPD, pain and CNS," said Mr. Dao.

MFMT(TM) drugs, a Genyous innovation, possess multiple therapeutic functions and act upon multiple biological targets to treat complex chronic diseases. These multivalent therapies were designed using a systems biology strategy that takes into consideration crosstalk between cells, their microenvironment and the host organism (e.g. the immune system response). The comprehensive therapeutic activity profile of MFMT(TM) drugs represents an opportunity to significantly improve outcomes. By possessing multiple therapeutic functions and working through a multiplicity of biological targets, relatively low and well-tolerated doses of therapeutic actives are sufficient to treat diseases while minimizing disruption of and restoring the body's homeostasis. This unique characteristic of MFMT(TM) drug candidates leads to less risk of toxicity, side effects and development of drug resistance.

Chronic diseases are now at the center of America's healthcare crisis. According to the U.S. Centers for Disease Control and Prevention, an estimated 133 million people (more than one in three Americans), live with at least one chronic condition and the number continues to grow rapidly. Seventy-five percent of the $2.1 trillion spent on healthcare in the U.S. goes to treating people who suffer from chronic conditions. However, the efficacy and safety of these therapies for chronic diseases has not improved significantly for the past 50 years. For example the cancer mortality rate in the U.S. has only decreased by 5 percent since 1950.

About Genyous Biomed International Inc.

Genyous Biomed International Inc., www.genyous.com, was founded in 2000 to find new solutions for treating chronic diseases. The Company has developed the novel Multifunctional Multitargeted (MFMT(TM)) drug development platform to create multivalent drugs designed to address the heterogeneous nature of chronic diseases. Our lead drug candidates are poised for clinical trials in numerous therapeutic areas including cancer, pain, CNS and pre-cancerous indications such as BPH and COPD.


'/>"/>
SOURCE Genyous Biomed International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Environmental Tectonics Corporations BioMedical Division Announces Additional Sales of Hyperbaric Monoplace Chambers
2. USC awarded $22.2M NIH national biomedical informatics infrastructure coordinating center contract
3. BioMed Realty Trusts Center for Life Science Boston Now 91% Leased
4. BioMed Realty Trust Announces Tax Treatment of 2008 Distributions
5. Alpine Biomed Acquires Stellate to Create New Leader in Neurology Diagnostics Market
6. BioMedical Enterprises, Inc. (BME) Announces the Appointment of Kenneth I. Moch as President and Chief Executive Officer
7. Collexis BiomedExperts Hits 80,000 Registered Users Within the First Year!
8. 5,000 Medical Leaders Report Latest Advancements in Biomedical Technologies; Breakthroughs by 2015 Predicted for Alzheimer's, Heart Disease, Cancer, and Diabetes
9. Stem Cells Poised to Grow Organs for Transplant : Zannos Grekos, MD Presents Clinical Data of Research with Adult Stem Cells to Physicians at International Regenerative Biomedicine Conference
10. Response Biomedical Corporation Announces Change of Executives
11. AutismActionPlan.org Launches Doctor-Driven Biomedical Autism Treatment Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: